Marco Villanueva-Reza

Dr. Marco Villanueva-Reza

INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIA - INER, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2018 in Current Treatment Options in Infectious Diseases
Verified
Journal Article
Closed access
PDF file
AGArturo Galindo-Fraga
Arturo Galindo-Fraga
MVMarco Villanueva-Reza
Marco Villanueva-Reza
EOEric Ochoa
Eric Ochoa

30 January 2026 in Viruses
Verified
Journal Article
Open access
PDF file
PVPatricia Volkow
Patricia Volkow
MVMarco Villanueva-Reza
Marco Villanueva-Reza
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
EMEnrique Mendoza-Ramirez
Enrique Mendoza-Ramirez
AVAmérica Citlali Vera-Jimenez
América Citlali Vera-Jimenez
JVJoel Armando Vazquez-Perez
Joel Armando Vazquez-Perez
Immunocompromised patients, including those with advanced HIV infection, hematologic malignancies treated with anti-CD20 monoclonal antibodies, or combined immunodeficiencies, are at increased risk of persistent SARS-CoV-2 infection. While long-term viral shedding has been described in these patients, the extent and nature of intra-host viral evolution during long-term infection remain insufficiently documented. In this study, we report longitudinal genomic analyses of SARS-CoV-2 from three immunocompromised individuals with persistent COVID-19: (i) a female patient with follicular lymphoma receiving bendamustine-rituximab therapy with 9 months of persistence, (ii) a male patient with advanced HIV infection following prolonged antiretroviral therapy interruption with 10 months of persistence, and (iii) a female patient with Good’s Syndrome characterized by combined humoral and cellular immune deficiency with apparently four years of persistence. Replication-competent virus was detected over extended periods. Sequential whole-genome sequencing revealed the gradual accumulation of non-synonymous mutations across multiple viral genes, consistent with ongoing viral replication and intra-host diversification in the absence of effective immune control. Although based on a limited number of cases, these findings provide descriptive evidence that persistent SARS-CoV-2 infection in immunocompromised hosts can be associated with sustained viral evolution. This work highlights the importance of continued virological monitoring in selected patients with prolonged infection and contributes to the understanding of SARS-CoV-2 dynamics in settings of impaired immunity.

26 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
AHAlejandra Hernández-Terán
Alejandra Hernández-Terán
PGPamela Garcíadiego-Fossas
Pamela Garcíadiego-Fossas
MVMarco Villanueva-Reza
Marco Villanueva-Reza
CBCelia Boukadida
Celia Boukadida
BTBlanca Taboada
Blanca Taboada
JVJoel Armando Vazquez-Perez
Joel Armando Vazquez-Perez
Coronavirus disease 2019 (COVID-19) vaccines effectively protect against severe disease and death. However, the impact of the vaccine used, viral variants, and host factors on disease severity remain poorly understood. This work aimed to compare COVID-19 clinical presentations and outcomes in vaccinated and unvaccinated patients in Mexico City. From March to September 2021, clinical, demographic characteristics, and viral variants were obtained from 1014 individuals with a documented SARS-CoV-2 infection. We compared unvaccinated, partially vaccinated, and fully vaccinated patients, stratifying by age groups. We also fitted multivariate statistical models to evaluate the impact of vaccination status, SARS-CoV-2 lineages, vaccine types, and clinical parameters. Most hospitalized patients were unvaccinated. In patients over 61 years old, mortality was significantly higher in unvaccinated compared to fully vaccinated individuals. In patients aged 31 to 60 years, vaccinated patients were more likely to be outpatients (46%) than unvaccinated individuals (6.1%). We found immune disease and age above 61 years old to be risk factors, while full vaccination was found to be the most protective factor against in-hospital death. This study suggests that vaccination is essential to reduce mortality in a comorbid population such as that of Mexico.

5 June 2023
Verified
Preprint
Open access
PDF file
MVMarco Villanueva-Reza
Marco Villanueva-Reza
This is a very interesting review focusing not on the pathogen but on the population with direct and indirect effects on the muscle that leads to sarcopenia. I see this article with an impact on sarcopenia awareness but a potential to also lead to fu...

11 December 2023
Verified
Preprint
Open access
PDF file
MVMarco Villanueva-Reza
Marco Villanueva-Reza
Hello everyone. I do bring some recommendations to improve this article. Attention for dengue is usually centred on diagnosis, treatment, and prevention. Therapy without antivirals is generally focused on fluid, analgesics and supportive care. Se...